AR107117A1 - VARIANTS OF THE HUMAN LEUCOCITARY ANTIGEN (HLA CLASS 1) AND COMBINATIONS OF SUCH PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER TYPES OF CANCER - Google Patents
VARIANTS OF THE HUMAN LEUCOCITARY ANTIGEN (HLA CLASS 1) AND COMBINATIONS OF SUCH PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER TYPES OF CANCERInfo
- Publication number
- AR107117A1 AR107117A1 ARP160103969A ARP160103969A AR107117A1 AR 107117 A1 AR107117 A1 AR 107117A1 AR P160103969 A ARP160103969 A AR P160103969A AR P160103969 A ARP160103969 A AR P160103969A AR 107117 A1 AR107117 A1 AR 107117A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- cancer
- variants
- hla class
- immunotherapy against
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se refiere a variantes HLA clase 1, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, se refiere a la inmunoterapia contra el cáncer. Se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.The present disclosure relates to HLA class 1 variants, proteins, nucleic acids and cells intended for use in immunotherapeutic methods. In particular, it refers to immunotherapy against cancer. It also refers to peptide epitopes for T lymphocytes associated with tumors, alone or in combination with other peptides associated with tumors that, for example, can serve as pharmaceutical active ingredients in vaccine compositions intended to stimulate antitumor immune responses, or to stimulate ex vivo T lymphocytes which will then be transferred to the patients. Peptides bound to major histocompatibility complex (MHC) molecules, or peptides as such, can also be targets of antibodies, soluble T-lymphocyte receptors, and other binding molecules.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270968P | 2015-12-22 | 2015-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107117A1 true AR107117A1 (en) | 2018-03-21 |
Family
ID=61768614
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103969A AR107117A1 (en) | 2015-12-22 | 2016-12-21 | VARIANTS OF THE HUMAN LEUCOCITARY ANTIGEN (HLA CLASS 1) AND COMBINATIONS OF SUCH PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER TYPES OF CANCER |
| ARP210101588A AR122594A2 (en) | 2015-12-22 | 2021-06-10 | PEPTIDE, FUSION PROTEIN, T-CELL RECEPTOR, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-CELL, KIT, COMPOSITION, AND RELATED METHODS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101588A AR122594A2 (en) | 2015-12-22 | 2021-06-10 | PEPTIDE, FUSION PROTEIN, T-CELL RECEPTOR, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-CELL, KIT, COMPOSITION, AND RELATED METHODS |
Country Status (1)
| Country | Link |
|---|---|
| AR (2) | AR107117A1 (en) |
-
2016
- 2016-12-21 AR ARP160103969A patent/AR107117A1/en unknown
-
2021
- 2021-06-10 AR ARP210101588A patent/AR122594A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR122594A2 (en) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018003860A2 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other types of cancer | |
| CL2023001346A1 (en) | Use of peptides in immunotherapy against small cell lung cancer and others. | |
| CO2018010284A2 (en) | Treatments against uterine cancer | |
| CO2018002202A2 (en) | Peptides and combinations of peptides for immunotherapy against prostate cancer and other types of cancer | |
| CO2017008902A2 (en) | Peptides and new combinations of peptides for immunotherapy against lung cancer, including amicrocytic lung cancer and other types of cancer | |
| CO2018003659A2 (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other types of cancer | |
| CR20180398A (en) | PEPTIDES, COMBINATIONS OF PEPTIDES AND CELLS FOR USE IN IMMUNOTHERAPY AGAINST BLADDER CANCER AND OTHER TYPES OF CANCER | |
| CO2018000252A2 (en) | Peptides and combinations of peptides for immunotherapy against epithelial ovarian cancer and other types of cancer | |
| CR20180245A (en) | NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TYPES OF CANCER | |
| CO2017012891A2 (en) | Peptides and combinations of peptides for immunotherapy against ovarian cancer and other types of cancer | |
| CR20180001A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER. | |
| AR103220A1 (en) | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (CHC) AND OTHER TYPES OF CANCER | |
| CR20180051A (en) | NEW CELLULAR EPITHOPES AND NEW COMBINATIONS OF CELLULAR EPITHOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER TYPES OF CANCER. | |
| CR20180423A (en) | NEW PEPTIDES, COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER (Divisional 2018-0174) | |
| CO2018000245A2 (en) | Peptides and combinations of peptides for immunotherapy against pancreatic cancer and other types of cancer | |
| CO2019008008A2 (en) | New peptides and new peptide combinations for use in immunotherapy against ovarian and other cancers | |
| CO2019012077A2 (en) | Peptides and combinations thereof for use in immunotherapy against various types of cancer | |
| CO2018002902A2 (en) | Peptides and peptide combinations for the immunotherapeutic treatment of various types of cancer | |
| CO2018012294A2 (en) | Immunotherapy against melanoma and other types of cancer | |
| CO2018004869A2 (en) | Peptides and combination of peptides for immunotherapy against various types of cancer | |
| CL2023001324A1 (en) | Peptides, combinations, cells for immunotherapy against bladder cancer and other cancers | |
| CL2020002935A1 (en) | Peptides for use in cancer immunotherapy | |
| CL2024000530A1 (en) | Peptides and combinations, their use in immunotherapy against lung cancer and other cancers | |
| CL2021001011A1 (en) | Peptides and peptide combinations for use in immunotherapy against small cell lung cancer and other types of cancer (divisional application no. 201800780) | |
| CO2017009101A2 (en) | Peptides and peptide combination |